Over the past few years, large investments have been made in genome-wide association
studies (GWAS) with the expectation that some of these studies would lead to the identification …

… -disease pairs and to better prioritize candidates for drug repositioning, we further cross-referenced
all pairs with the clinical trial registry (http://clinicaltrials.gov). We sorted the 52,966 …

… GWAS may be used to construct drug-related networks, aiding drug repositioning. Although
… drug repositioning. We obtained drug target genes and corresponding drug information from …

… drug repositioning have been developed, but methods utilizing genome-wide association
studies … A schematic diagram showing the five drug repositioning approaches reviewed in this …

… opportunities for repurposing existing drugs, also known as drug repositioning. These
approaches … , transcriptome-wide association studies, gene-set association, causal inference by …

… Association studies, however, identify disease susceptibility variants that do not necessarily
mean the variant is important in disease causation. It is an easier task to identify gene-…

… Genome-wide association studies (GWAS) in PD have … drug repositioning by integrating
weighted drug-protein regulations on all genes, using our novel DESS to quantitate drug effects …

… drug-disease associations can speed up drug repositioning … prior biological information for
association inference. However, … these predicted associations would benefit drug research. …

… In the April 2012 issue, Sanseau et al. proposed the use of genome-wide association studies
(GWAS) for drug repositioning 4 . This strategy is consistent with the concept that human …

… -based drug repositioning strategy and integrated the two distinct perspectives of rational
drug repositioning to obtain more reliable and ranked drug repositioning results. We …